Superlab Suisse to Open at Campus Biotech in 2026
Share this article
Superlab Suisse, a leading provider of next-generation lab infrastructure, has announced the opening of a fully serviced lab facility at Campus Biotech in Geneva, scheduled for January 2026. This milestone marks a significant step in the evolution of Geneva as one of the most dynamic and fast-growing life science clusters in the world.
Located at the heart of Campus Biotech, Superlab Suisse Geneva will offer ready-to-move-in laboratories designed to meet the diverse needs of biotech startups, scale-ups, and research-driven companies. With flexible lab configurations, shared advanced equipment, and full operational support—including biosafety, waste management, and compliance—Superlab Suisse is redefining what it means to launch and scale in life sciences.
“Geneva is rising as one of the most dynamic life science clusters in the world,” said Xi Zhang, Founder and CEO of Superlab Suisse. “With global institutions, cutting-edge research, and a fast-growing biotech sector, Geneva is shaping the future of life sciences — and Superlab Suisse is here to build what comes next.”
The Geneva site will also feature a range of common areas including a cell culture room, LN2 cryo room, chemical waste handling, autoclave facilities, and collaborative community spaces. In addition to infrastructure, tenants benefit from direct access to a vibrant ecosystem of investors, advis
ors, and scientific events, as well as exclusive e-commerce discounts through pre-negotiated lab supplier partnerships.
“Geneva is rapidly becoming a global hub for life sciences, where research and innovation come together,” said Igor Fisch, Chair of FONGIT and a renowned life sciences entrepreneur. “We’re proud to support Superlab Suisse’s expansion to Campus Biotech, providing startups with access to world-class infrastructure.”
Superlab Suisse is building a global network of lab facilities with sites across Europe, the US, and Asia, empowering biotech teams to start and grow faster. Its Lausanne facility already hosts Haya Therapeutics, which recently made headlines with a $1 billion partnership with Eli Lilly and a $65 million Series A funding round — showcasing Superlab’s role as a true launch pad for success.